Mersana Therapeutics Statistics
Share Statistics
Mersana Therapeutics has 123.53M shares outstanding. The number of shares has increased by 1.74% in one year.
| Shares Outstanding | 123.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 86.56M |
| Failed to Deliver (FTD) Shares | 14.18K |
| FTD / Avg. Volume | 1.35% |
Short Selling Information
The latest short interest is 9.87M, so 7.99% of the outstanding shares have been sold short.
| Short Interest | 9.87M |
| Short % of Shares Out | 7.99% |
| Short % of Float | 11.44% |
| Short Ratio (days to cover) | 14.04 |
Valuation Ratios
The PE ratio is -1.57 and the forward PE ratio is -3.14.
| PE Ratio | -1.57 |
| Forward PE | -3.14 |
| PS Ratio | 7.31 |
| Forward PS | 9.3 |
| PB Ratio | 7.3 |
| P/FCF Ratio | -1.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Mersana Therapeutics Inc. has an Enterprise Value (EV) of 128.65M.
| EV / Earnings | -0.75 |
| EV / Sales | 3.49 |
| EV / EBITDA | -0.77 |
| EV / EBIT | -0.75 |
| EV / FCF | -0.75 |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.68.
| Current Ratio | 3.36 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.68 |
| Total Debt / Capitalization | 40.61 |
| Cash Flow / Debt | -6.69 |
| Interest Coverage | -41.97 |
Financial Efficiency
Return on equity (ROE) is -4.65% and return on capital (ROIC) is -241.69%.
| Return on Equity (ROE) | -4.65% |
| Return on Assets (ROA) | -0.76% |
| Return on Capital (ROIC) | -241.69% |
| Revenue Per Employee | 299.63K |
| Profits Per Employee | -1.40M |
| Employee Count | 123 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 4.88% in the last 52 weeks. The beta is 1.48, so Mersana Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.48 |
| 52-Week Price Change | 4.88% |
| 50-Day Moving Average | 2.17 |
| 200-Day Moving Average | 2.58 |
| Relative Strength Index (RSI) | 50.32 |
| Average Volume (20 Days) | 1.05M |
Income Statement
In the last 12 months, Mersana Therapeutics had revenue of $36.85M and earned -$171.67M in profits. Earnings per share was $-1.48.
| Revenue | 36.85M |
| Gross Profit | -111.41M |
| Operating Income | -170.96M |
| Net Income | -171.67M |
| EBITDA | -166.08M |
| EBIT | -170.96M |
| Earnings Per Share (EPS) | -1.48 |
Balance Sheet
The company has $174.56M in cash and $33.83M in debt, giving a net cash position of $140.73M.
| Cash & Cash Equivalents | 174.56M |
| Total Debt | 33.83M |
| Net Cash | 140.73M |
| Retained Earnings | -826.36M |
| Total Assets | 169.53M |
| Working Capital | 92.26M |
Cash Flow
In the last 12 months, operating cash flow was -$168.88M and capital expenditures -$2.17M, giving a free cash flow of -$171.05M.
| Operating Cash Flow | -168.88M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -171.05M |
| FCF Per Share | -1.47 |
Margins
Gross margin is -302.3%, with operating and profit margins of -463.86% and -465.8%.
| Gross Margin | -302.3% |
| Operating Margin | -463.86% |
| Pretax Margin | -465.8% |
| Profit Margin | -465.8% |
| EBITDA Margin | -450.63% |
| EBIT Margin | -463.86% |
| FCF Margin | -464.12% |
Dividends & Yields
MRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -68.84% |
| FCF Yield | -64.55% |
Analyst Forecast
The average price target for MRSN is $6, which is 179.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 179.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -6.77 |
| Piotroski F-Score | 3 |